Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel J Brooks

Showing results (41-50 of 89) with videos related to

Pageof 9
Sort By:
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|January 12, 2016
1,25-Dihydroxyvitamin D Alone Improves Skeletal Growth, Microarchitecture, and Strength in a Murine Model of XLH, Despite Enhanced FGF23 ExpressionEva S Liu, Janaina S Martins, Adalbert Raimann, et al.
Plos One|June 4, 2021
TRPM8 modulates temperature regulation in a sex-dependent manner without affecting cold-induced bone lossAdriana Lelis Carvalho, Annika Treyball, Daniel J Brooks, et al.
Bone|December 18, 2020
Abaloparatide treatment increases bone formation, bone density and bone strength without increasing bone resorption in a rat model of hindlimb unloadingDian A Teguh, Jordan L Nustad, Amanda E Craven, et al.
The American Journal of Drug and Alcohol Abuse|February 9, 2018
Open-label pilot study of injectable naltrexone for cannabis dependenceDaniel P Notzon, Meredith A Kelly, C Jean Choi, et al.
Drug and Alcohol Dependence|January 8, 2021
Lorcaserin treatment for extended-release naltrexone induction and retention for opioid use disorder individuals: A pilot, placebo-controlled randomized trialFrances R Levin, John J Mariani, Martina Pavlicova, et al.
The American Journal on Addictions|July 5, 2021
Open-label trial of a single-day induction onto buprenorphine extended-release injection for users of heroin and fentanylJohn J Mariani, Amy L Mahony, Samuel C Podell, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 6, 2025
Mechanism and application of thiol-disulfide redox biosensors with a fluorescence-lifetime readoutPaul C Rosen, Andrew Glaser, Juan R Martínez-François, et al.
Addiction (Abingdon, England)|January 10, 2013
A randomized double-blind, placebo-controlled trial of venlafaxine-extended release for co-occurring cannabis dependence and depressive disordersFrances R Levin, John Mariani, Daniel J Brooks, et al.
JCI Insight|October 23, 2023
Comparative study in estrogen-depleted mice identifies skeletal and osteocyte transcriptomic responses to abaloparatide and teriparatideZhengtao Lv, Jiaming Zhang, Shuang Liang, et al.
The American Journal of Drug and Alcohol Abuse|October 4, 2023
Open label trial of lofexidine-assisted non-opioid induction onto naltrexone extended-release injection for opioid use disorderJohn J Mariani, Cale Basaraba, Martina Pavlicova, et al.
Pageof 9

Showing results (41-50 of 89) with videos related to

Sort By:
Pageof 9
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|January 12, 2016
1,25-Dihydroxyvitamin D Alone Improves Skeletal Growth, Microarchitecture, and Strength in a Murine Model of XLH, Despite Enhanced FGF23 ExpressionEva S Liu, Janaina S Martins, Adalbert Raimann, et al.
Plos One|June 4, 2021
TRPM8 modulates temperature regulation in a sex-dependent manner without affecting cold-induced bone lossAdriana Lelis Carvalho, Annika Treyball, Daniel J Brooks, et al.
Bone|December 18, 2020
Abaloparatide treatment increases bone formation, bone density and bone strength without increasing bone resorption in a rat model of hindlimb unloadingDian A Teguh, Jordan L Nustad, Amanda E Craven, et al.
The American Journal of Drug and Alcohol Abuse|February 9, 2018
Open-label pilot study of injectable naltrexone for cannabis dependenceDaniel P Notzon, Meredith A Kelly, C Jean Choi, et al.
Drug and Alcohol Dependence|January 8, 2021
Lorcaserin treatment for extended-release naltrexone induction and retention for opioid use disorder individuals: A pilot, placebo-controlled randomized trialFrances R Levin, John J Mariani, Martina Pavlicova, et al.
The American Journal on Addictions|July 5, 2021
Open-label trial of a single-day induction onto buprenorphine extended-release injection for users of heroin and fentanylJohn J Mariani, Amy L Mahony, Samuel C Podell, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 6, 2025
Mechanism and application of thiol-disulfide redox biosensors with a fluorescence-lifetime readoutPaul C Rosen, Andrew Glaser, Juan R Martínez-François, et al.
Addiction (Abingdon, England)|January 10, 2013
A randomized double-blind, placebo-controlled trial of venlafaxine-extended release for co-occurring cannabis dependence and depressive disordersFrances R Levin, John Mariani, Daniel J Brooks, et al.
JCI Insight|October 23, 2023
Comparative study in estrogen-depleted mice identifies skeletal and osteocyte transcriptomic responses to abaloparatide and teriparatideZhengtao Lv, Jiaming Zhang, Shuang Liang, et al.
The American Journal of Drug and Alcohol Abuse|October 4, 2023
Open label trial of lofexidine-assisted non-opioid induction onto naltrexone extended-release injection for opioid use disorderJohn J Mariani, Cale Basaraba, Martina Pavlicova, et al.
Pageof 9